Skip to main content

Advertisement

SpringerLink
Log in

Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus

  • Original Articles
  • Published:
Langenbeck's Archives of Surgery Aims and scope Submit manuscript

Abstract

Purpose

Some clinical studies have suggested that metformin improved prognoses in several cancers. This study aimed to identify prognostic factors for pancreatic ductal adenocarcinoma (PDAC) and determine the utility of metformin administration.

Methods

Between January 2007 and December 2015, 373 consecutive patients underwent curative surgery for PDAC. Among the patients, 121 were diagnosed as having diabetes mellitus (DM) before surgery. The characteristics and overall survival (OS) between patients with and without DM were compared retrospectively. Based on their metformin intake, patients with DM were divided into two groups. OS rates between patients with and without metformin intake were compared. Univariate and multivariate analyses were performed to identify prognostic factors for OS among all patients and those with PDAC and DM.

Results

No significant differences in the 5-year survival rates between patients with and without DM were observed. Among the 121 patients with DM, 18 received metformin and 103 did not (other medications group). The 5-year survival rate was significantly better in the metformin group than in the other medications group (66.7% and 24.4%, respectively; p = 0.034). Multivariate analysis identified pN1 (p = 0.002), metformin administration (p = 0.022), and microvascular invasion (p = 0.023) as independent prognostic factors for OS in the patients with DM. Matched-pair analysis showed that OS tended to be better in the metformin group than in the other medications group (p = 0.067).

Conclusions

History of metformin intake may contribute to favorable prognosis in patients with PDAC and pre-existing DM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34

    Article  PubMed  Google Scholar 

  2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108

    Article  PubMed  Google Scholar 

  3. Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388:248–257

    Article  CAS  PubMed  Google Scholar 

  4. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310:1473–1481

    Article  CAS  PubMed  Google Scholar 

  5. Magruder JT, Elahi D, Andersen DK (2011) Diabetes and pancreatic cancer: chicken or egg? Pancreas 40:339–351

    Article  PubMed  Google Scholar 

  6. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N (2013) Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31:3069–3075

    Article  CAS  PubMed  Google Scholar 

  7. Coyle C, Cafferty FH, Vale C, Langley RE (2016) Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol 27:2184–2195

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kumar S, Meuter A, Thapa P, Langstraat C, Giri S, Chien J, Rattan R, Cliby W, Shridhar V (2013) Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer 119:555–562

    Article  CAS  PubMed  Google Scholar 

  9. Xu H, Chen K, Jia X, Tian Y, Dai Y, Li D, Xie J, Tao M, Mao Y (2015) Metformin use is associated with better survival of breast cancer patients with diabetes: a meta-analysis. Oncologist 20:1236–1244

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, Knox J, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, Bekaii-Saab T, McNamara MG, Valle JW (2016) Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol 27:134–140

    Article  CAS  PubMed  Google Scholar 

  11. Wan G, Sun X, Li F, Wang X, Li C, Li H, Yu X, Cao F (2018) Survival benefit of metformin adjuvant treatment for pancreatic cancer patients: a systematic review and meta-analysis. Cell Physiol Biochem 49:837–847

    Article  CAS  PubMed  Google Scholar 

  12. Zhou PT, Li B, Liu FR, Zhang MC, Wang Q, Li YY, Xu C, Liu YH, Yao Y, Li D (2017) Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. Oncotarget 8:25242–25250

    Article  PubMed  PubMed Central  Google Scholar 

  13. Dong YW, Shi YQ, He LW, Cui XY, Su PZ (2017) Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis. Oncotarget 8:55478–55488

    Article  PubMed  PubMed Central  Google Scholar 

  14. Jang WI, Kim MS, Kang SH, Jo AJ, Kim YJ, Tchoe HJ, Park CM, Kim HJ, Choi JA, Choi HJ, Paik EK, Seo YS, Yoo HJ, Kang JK, Han CJ, Kim YJ, Kim SB, Ko MJ (2017) Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in Korea. Oncotarget 8:9587–9596

    Article  PubMed  Google Scholar 

  15. Amin S, Mhango G, Lin J, Aronson A, Wisnivesky J, Boffetta P, Lucas AL (2016) Metformin improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes: a propensity score analysis. Am J Gastroenterol 111:1350–1357

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Choi Y, Kim TY, Oh DY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ (2016) The impact of diabetes mellitus and metformin treatment on survival of patients with advanced pancreatic cancer undergoing chemotherapy. Cancer Res Treat 48:171–179

    Article  CAS  PubMed  Google Scholar 

  17. Ambe CM, Mahipal A, Fulp J, Chen L, Malafa MP (2016) Effect of metformin use on survival in resectable pancreatic cancer: a single-institution experience and review of the literature. PLoS One 11:e0151632

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Wang Z, Lai ST, Xie L, Zhao JD, Ma NY, Zhu J, Ren ZG, Jiang GL (2014) Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 106:19–26

    Article  CAS  PubMed  Google Scholar 

  19. Sadeghi N, Abbruzzese JL, Yeung SC et al (2012) Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 18:2905–2912

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Currie CJ, Poole CD, Jenkins-Jones S, Gale EAM, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35:299–304

    Article  PubMed  PubMed Central  Google Scholar 

  21. Chaiteerakij R, Petersen GM, Bamlet WR, Chaffee KG, Zhen DB, Burch PA, Leof ER, Roberts LR, Oberg AL (2016) Metformin use and survival of patients with pancreatic cancer: a cautionary lesson. J Clin Oncol 34:1898–1904

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Kordes S, Pollak MN, Zwinderman AH, Mathôt RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW (2015) Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 16:839–847

    Article  CAS  PubMed  Google Scholar 

  23. Hwang AL, Haynes K, Hwang WT, Yang YX (2013) Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas 42:1054–1059

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. World Health Organization, Geneva

  25. (2011) Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. World Health Organization, Geneva

  26. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196

    Article  PubMed  Google Scholar 

  27. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink MG, Conlon K, del Chiaro M, Falconi M, Fernandez-Cruz L, Fernandez-del Castillo C, Fingerhut A, Friess H, Gouma DJ, Hackert T, Izbicki J, Lillemoe KD, Neoptolemos JP, Olah A, Schulick R, Shrikhande SV, Takada T, Takaori K, Traverso W, Vollmer CR, Wolfgang CL, Yeo CJ, Salvia R, Buchler M, International Study Group on Pancreatic Surgery (ISGPS) (2017) The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery 161:584–591

    Article  PubMed  Google Scholar 

  28. Ohgi K, Yamamoto Y, Sugiura T, Okamura Y, Ito T, Ashida R, Aramaki T, Uesaka K (2017) Is pancreatic head cancer with portal venous involvement really borderline resectable? Appraisal of an upfront surgery series. Ann Surg Oncol 24:2752–2761

    Article  PubMed  Google Scholar 

  29. Brierley JGM, Wittekind C (2017) UICC TNM classification of malignant tumours, Eighth edn. Wiley, Chichester

    Google Scholar 

  30. Andersen DK, Korc M, Petersen GM, Eibl G, Li D, Rickels MR, Chari ST, Abbruzzese JL (2017) Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes 66:1103–1110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Hwang A, Narayan V, Yang Y-X (2013) Type 2 diabetes mellitus and survival in pancreatic adenocarcinoma: a retrospective cohort study. Cancer 119:404–410

    Article  PubMed  Google Scholar 

  32. McWilliams RR, Matsumoto ME, Burch PA et al (2010) Obesity adversely affects survival in pancreatic cancer patients. Cancer 116:5054–5062

    Article  PubMed  Google Scholar 

  33. Chu CK, Mazo AE, Goodman M, Egnatashvili V, Sarmiento JM, Staley CA, Galloway JR, Adsay NV, Jacobs S, Kooby DA (2010) Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol 17:502–513

    Article  PubMed  Google Scholar 

  34. Cannon RM, LeGrand R, Chagpar RB, Ahmad SA, McClaine R, Kim HJ, Rupp C, Cho CS, Brinkman A, Weber S, Winslow ER, Kooby DA, Chu CK, Staley CA, Glenn I, Hawkins WG, Parikh AA, Merchant NB, McMasters KM, Martin RCG, Callender GG, Scoggins CR (2012) Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. HPB 14:228–235

    Article  PubMed  PubMed Central  Google Scholar 

  35. Mao Y, Tao M, Jia X, Li D (2015) Diabetes associated with short survival in pancreatic cancer. J Clin Oncol 33:2120–2121

    Article  PubMed  Google Scholar 

  36. Roeyen G, Jansen M, Chapelle T, Bracke B, Hartman V, Ysebaert D, de Block C (2016) Diabetes mellitus and pre-diabetes are frequently undiagnosed and underreported in patients referred for pancreatic surgery. A prospective observational study. Pancreatology 16:671–676

    Article  PubMed  Google Scholar 

  37. Warburg O (1956) On the origin of cancer cells. Science 123:309–314

    Article  CAS  PubMed  Google Scholar 

  38. Jalving M, Gietema JA, Lefrandt JD et al (2010) Metformin: taking away the candy for cancer? Eur J Cancer 46:2369–2380

    Article  CAS  PubMed  Google Scholar 

  39. Yue W, Yang CS, DiPaola RS et al (2014) Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res (Phila) 7:388–397

    Article  CAS  Google Scholar 

  40. Singh P, Alex JM, Bast F (2014) Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Med Oncol 31:805

    Article  PubMed  CAS  Google Scholar 

  41. Pan YH, Jiao L, Lin CY, Lu CH, Li L, Chen HY, Wang YB, He Y (2018) Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway. Biologics 12:75–86

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Han G, Gong H, Wang Y, Guo S, Liu K (2015) AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther 16:77–87

    Article  CAS  PubMed  Google Scholar 

  43. Tan XL, Bhattacharyya KK, Dutta SK, Bamlet WR, Rabe KG, Wang E, Smyrk TC, Oberg AL, Petersen GM, Mukhopadhyay D (2015) Metformin suppresses pancreatic tumor growth with inhibition of NFkappaB/STAT3 inflammatory signaling. Pancreas 44:636–647

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Kourelis TV, Siegel RD (2012) Metformin and cancer: new applications for an old drug. Med Oncol 29:1314–1327

    Article  CAS  PubMed  Google Scholar 

  45. Bridges HR, Jones AJ, Pollak MN et al (2014) Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 462:475–487

    Article  CAS  PubMed  Google Scholar 

  46. Memmott RM, Dennis PA (2009) LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol 27:e226

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan

    Fumihiro Terasaki, Teiichi Sugiura, Yukiyasu Okamura, Takaaki Ito, Yusuke Yamamoto, Ryo Ashida, Katsuhisa Ohgi & Katsuhiko Uesaka

Authors
  1. Fumihiro Terasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teiichi Sugiura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yukiyasu Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takaaki Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yusuke Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ryo Ashida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Katsuhisa Ohgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Katsuhiko Uesaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study conception and design: FT and TS. Acquisition of data: FT and TS. Analysis and interpretation of data: FT, TS, and YY. Drafting of manuscript: FT, TS, and KU. Critical revision of manuscript: all authors.

Corresponding author

Correspondence to Teiichi Sugiura.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study. Our study protocols can be obtained from our institutional website.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Terasaki, F., Sugiura, T., Okamura, Y. et al. Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus. Langenbecks Arch Surg 405, 313–324 (2020). https://doi.org/10.1007/s00423-020-01874-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00423-020-01874-3

Keywords

Search

Navigation